Neurobo Pharmaceuticals Inc (NRBO) Key Ratios
$1.89
As on 29-Jan-2025 09:30EDT
Market cap
$20 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 37.93 | -60.73 | -24.16 | 15.66 | -37.68 |
| Net Profit | 43.78 | -48.04 | -344.01 | 14.72 | -138.64 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -226,957.14 | -226,957.14 | -640,975.00 | -226,957.14 | -- |
| Net Margin
| -- | -- | -693,325.00 | -- | -- |
| Return on equity
| -79.40 | -94.35 | -240.85 | -64.89 | -33.65 |
| Return on Capital
| -78.91 | -90.95 | -- | -64.55 | -33.58 |
| Return on Assets
| -59.41 | -108.45 | -88.88 | -44.29 | -24.30 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.01 | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
--
|
-64.55
|
-33.58
|
-138.60
|
-300.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-240.85
Lower than Peers by 200.52
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-240.85
|
-64.89
|
-33.65
|
-139.65
|
-303.60
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-88.88
Lower than Peers by 57.63
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-88.88
|
-44.29
|
-24.30
|
-109.64
|
-232.69
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-640,975.00
Lower than Peers by 640,892.40
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-640,975.00
|
-226,957.14
|
--
|
--
|
--
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-693,325.00
Lower than Peers by 693,233.70
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-693,325.00
|
-178,142.86
|
--
|
--
|
--
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-36.49
Lower than Peers by 36.49
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-36.49
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
EBIT Growth
-24.16
Lower than Peers by 23.14
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-24.16
|
-39.04
|
25.31
|
48.52
|
-47.28
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-344.01
Lower than Peers by 336.48
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-344.01
|
-103.92
|
59.83
|
48.56
|
-31.93
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
--
|
0.01
|
--
|
0.00
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
0.01
|
0.01
|
--
|
0.00
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.41
Lower than Peers by 3.40
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
2.41
|
3.78
|
2.85
|
7.69
|
2.89
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
2.41
Lower than Peers by 3.29
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
2.41
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-329.15
Lower than Peers by 327.07
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-329.15
|
--
|
-5.21
|
-1,092.71
|
-761.95
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
0.00
|
0.00
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
--
|
39,890.52
|
10,031.33
|
8,636.64
|
8,757.82
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
1.32
Lower than Peers by 4.01
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
1.32
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.43
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
-0.43
|
1.40
|
2.93
|
1.07
|
0.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
20
Lower than Peers by 121
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
20
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|